Thursday, July 11, 2024

CATEGORY

Novartis

Psoriatic Arthritis Care in Canada: Novartis and Clarius Announce Partnership

Psoriatic arthritis care in Canada is set to improve significantly as Novartis Pharmaceuticals Canada partners with Clarius Mobile Health to enhance access to advanced...

Chronic Myeloid Leukemia: Scemblix® Receives FDA Breakthrough Therapy Designation

Novartis has announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to Scemblix® (asciminib) for the treatment of adult...

Novartis Boosts Radioligand Therapy Program with Mariana Oncology Acquisition

Novartis, a global leader in pharmaceuticals, announced its strategic acquisition of Mariana Oncology, a biotech firm specializing in radioligand therapies (RLTs), marking a significant...

Breakthrough Brain Cancer Treatment for Children Approved by NICE

A groundbreaking new drug combination offering hope for children and teenagers with a severe form of brain cancer has received a recommendation from NICE...

Novel Malaria Treatment for Babies Under 5kg Shows Promising Results

In a significant advancement in pediatric healthcare, Novartis, in collaboration with Medicines for Malaria Venture (MMV), has recently unveiled encouraging efficacy and safety data...

A Groundbreaking Oral Therapy for Paroxysmal Nocturnal Hemoglobinuria: CHMP Endorses Novartis’ Fabhalta

In the recent meeting of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) held in March, a significant recommendation...

Novartis’ Study Expands Hope for Spinal Muscular Atrophy Patients: Zolgensma’s Efficacy in Older Children

Novartis revealed pivotal data underscoring the effectiveness and safety of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) in a demographic previously less...

The First and Only Pharmaceutical Food Allergy Therapy Xolair Gains New FDA Approval

As it nears the end of its patent life, Roche and Novartis' Xolair for food allergy is making significant strides by gaining groundbreaking new...

Therapy for Gastroenteropancreatic Neuroendocrine Tumors Novartis’ Lutathera® Cuts Risk by 72% in First-Line Treatment

The Phase III NETTER-2 trial has marked a significant advancement in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Novartis, a leader in radioligand therapy...

In Chronic Myeloid Leukemia Trial, Scemblix Exhibits Higher MMR Rates

Novartis has recently announced the groundbreaking results of its ASC4FIRST Phase III trial, which marks a significant advancement in the treatment of chronic myeloid...

Latest news